Msd R&d (china) Co., Ltd.
Clinical trials sponsored by Msd R&d (china) Co., Ltd., explained in plain language.
-
New immunotherapy MK-1045 enters first human trial for Hard-to-Treat lymphoma
Disease control Recruiting nowThis early-phase study tests MK-1045, an immunotherapy that helps the immune system fight cancer, in 100 adults with relapsed or refractory B-cell Non-Hodgkin lymphoma (a type of blood cancer that has returned or stopped responding to treatment). The main goals are to check safet…
Phase: PHASE1 • Sponsor: MSD R&D (China) Co., Ltd. • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
New hope for tough blood cancer: experimental drug MK-1045 enters key trials
Disease control Recruiting nowThis study tests a new drug called MK-1045 for people with a type of blood cancer (precursor B-cell acute lymphoblastic leukemia) that has returned or no longer responds to standard treatments. The study has two parts: first, finding a safe and tolerable dose, and second, checkin…
Phase: PHASE1, PHASE2 • Sponsor: MSD R&D (China) Co., Ltd. • Aim: Disease control
Last updated May 11, 2026 20:53 UTC